| 臺大學術典藏 |
2022-09-15T01:08:57Z |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler J.H.; LoRusso P.; Salgia R.; Kang Y.-K.; Yen C.J.; Chia-Chi Lin; Ansell P.; Motwani M.; Wong S.; Yue H.; Wang L.; Reilly E.; Afar D.; Naumovski L.; Ramanathan R.K. |
| 臺大學術典藏 |
2022-09-15T01:08:56Z |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai J.; Deva S.; Lee J.S.; Chia-Chi Lin; Yen C.-J.; Chao Y.; Keam B.; Jameson M.; Hou M.-M.; Kang Y.-K.; Markman B.; Lu C.-H.; Rau K.-M.; Lee K.-H.; Horvath L.; Friedlander M.; Hill A.; Sandhu S.; Barlow P.; Wu C.-Y.; Zhang Y.; Liang L.; Wu J.; Paton V.; Millward M. |
| 臺大學術典藏 |
2022-08-19T00:20:37Z |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T. |
| 臺大學術典藏 |
2022-08-19T00:20:36Z |
Corrigendum to ��Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis�� [J Hepatol 71 (2019) 543�V552](S0168827819303009)(10.1016/j.jhep.2019.05.014)
|
Kudo M.; Dela Cruz C.; Anderson J.; Zhao H.; Chao Y.; Moriguchi M.; Kuromatsu R.; Ikeda M.; Yeo W.; Chopra A.; Yau T.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K. |
| 臺大學術典藏 |
2022-06-10T06:10:56Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2022-01-05T03:36:40Z |
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
|
Kang Y.-K.; Morita S.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2022-01-05T03:36:39Z |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Nishiyama T.; Chen L.-T.; Kang Y.-K. |
| 國立成功大學 |
2022 |
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials
|
Kang, Y.-K.;Reck, M.;Nghiem, P.;Feng, Y.;Plautz, G.;Kim, H.R.;Owonikoko, T.K.;Boku, N.;Chen, L.-T.;Lei, M.;Chang, H.;Lin, W.H.;Roy, A.;Bello, A.;Sheng, J. |
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 國立成功大學 |
2022 |
A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors
|
Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P. |
| 臺大學術典藏 |
2021-09-01T01:54:24Z |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
|
ANN-LII CHENG; Kang Y.-K.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Luo R.; Feng J.; Ye S.; Yang T.-S.; Xu J.; Sun Y.; Liang H.; Liu J.; Wang J.; Tak W.Y.; Pan H.; Burock K.; Zou J.; Voliotis D.; Guan Z. |
| 臺大學術典藏 |
2021-09-01T01:54:07Z |
Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib
|
Faivre S.; Zappa M.; Vilgrain V.; Boucher E.; Douillard J.-Y.; Lim H.Y.; Kim J.S.; Im S.-A.; Kang Y.-K.; Bouattour M.; Dokmak S.; Dreyer C.; Sablin M.-P.; Serrate C.; ANN-LII CHENG; Lanzalone S.; Lin X.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-09-01T01:53:59Z |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
|
ANN-LII CHENG; Guan Z.; Chen Z.; Tsao C.-J.; Qin S.; Kim J.S.; Yang T.-S.; Tak W.Y.; Pan H.; Yu S.; Xu J.; Fang F.; Zou J.; Lentini G.; Voliotis D.; Kang Y.-K. |
| 臺大學術典藏 |
2021-09-01T01:53:56Z |
Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012
|
Ku G.; Tan I.B.; Yau T.; Boku N.; Laohavinij S.; ANN-LII CHENG; Kang Y.-K.; de Lima Lopes G. |
| 臺大學術典藏 |
2021-09-01T01:53:47Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; ANN-LII CHENG |
| 臺大學術典藏 |
2021-09-01T01:53:43Z |
Sunitinib versus sorafenib in advanced hepatocellular cancer: Results of a randomized phase III trial
|
ANN-LII CHENG; Kang Y.-K.; Lin D.-Y.; Park J.-W.; Kudo M.; Qin S.; Chung H.-C.; Song X.; Xu J.; Poggi G.; Omata M.; Lowenthal S.P.; Lanzalone S.; Yang L.; Lechuga M.J.; Raymond E. |
| 臺大學術典藏 |
2021-08-31T06:29:48Z |
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study
|
ANN-LII CHENG; Kang Y.-K.; He A.R.; Lim H.Y.; Ryoo B.-Y.; Hung C.-H.; Sheen I.-S.; Izumi N.; Austin T.; Wang Q.; Greenberg J.; Shiratori S.; Beckman R.A.; Kudo M. |
| 臺大學術典藏 |
2021-08-31T06:29:46Z |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma
|
ANN-LII CHENG; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P. |
| 臺大學術典藏 |
2021-08-11T03:46:35Z |
First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
|
Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. |
| 臺大學術典藏 |
2021-07-26T09:44:30Z |
Large expert-curated database for benchmarking document similarity detection in biomedical literature search
|
Brown P;Zhou Y;Tan A.-C;El-Esawi M.A;Liehr T;Blanck O;Gladue D.P;Almeida G.M.F;Cernava T;Sorzano C.O;Yeung A.W.K;Engel M.S;Chandrasekaran A.R;Muth T;Staege M.S;Daulatabad S.V;Widera D;Zhang J;Meule A;Honjo K;Pourret O;Yin C.-C;Zhang Z;Cascella M;Flegel W.A;Goodyear C.S;van Raaij M.J;Bukowy-Bieryllo Z;Campana L.G;Kurniawan N.A;Lalaouna D;H?ttner F.J;Ammerman B.A;Ehret F;Cobine P.A;Tan E.-C;Han H;Xia W;McCrum C;Dings R.P.M;Marinello F;Nilsson H;Nixon B;Voskarides K;Yang L;Costa V.D;Bengtsson-Palme J;Bradshaw W;Grimm D.G;Kumar N;Martis E;Prieto D;Sabnis S.C;Amer S.E.D.R;Liew A.W.C;Perco P;Rahimi F;Riva G;Zhang C;Devkota H.P;Ogami K;Basharat Z;Fierz W;Siebers R;Tan K.H;Boehme K.A;Brenneisen P;Brown J.A.L;Dalrymple B.P;Harvey D.J;Ng G;Werten S;Bleackley M;Dai Z;Dhariwal R;Gelfer Y;Hartmann M.D;Miotla P;Tamaian R;Govender P;Gurney-Champion O.J;Kauppila J.H;Zhang X;Echeverr?a N;Subhash S;Sallmon H;Tofani M;Bae T;Bosch O;Cu?v P.O;Danchin A;Diouf B;Eerola T;Evangelou E;Filipp F;Klump H;Kurgan L;Smith S.S;Terrier O;Tuttle N;Ascher D.B;Janga S.C;Schulte L.N;Becker D;Browngardt C;Bush S.J;Gaullier G;Ide K;Meseko C;Werner G.D.A;Zaucha J;Al-Farha A.A;Greenwald N.F;Popoola S.I;Rahman S;Xu J;Yang S.Y;Hiroi N;Alper O.M;Baker C.I;Bitzer M;Chacko G;Debrabant B;Dixon R;Forano E;Gilliham M;Kelly S;Klempnauer K.-H;Lidbury B.A;Lin M.Z;Lynch I;Ma W;Maibach E.W;Mather D.E;Nandakumar K.S;Ohgami R.S;Parchi P;Tressoldi P;Xue Y;Armitage C;Barraud P;Chatzitheochari S;Coelho L.P;Diao J;Doxey A.C;Gobet A;Hu P;Kaiser S;Mitchell K.M;Salama M.F;Shabalin I.G;Song H;Stevanovic D;Yadollahpour A;Zeng E;Zinke K;Alimba C.G;Beyene T.J;Cao Z;Chan S.S;Gatchell M;Kleppe A;Piotrowski M;Torga G;Woldesemayat A.A;Cosacak M.I;Haston S;Ross S.A;Williams R;Wong A;Abramowitz M.K;Effiong A;Lee S;Abid M.B;Agarabi C;Alaux C;Albrecht D.R;Atkins G.J;Beck C.R;Bonvin A.M.J.J;Bourke E;Brand T;Braun R.J;Bull J.A;Cardoso P;Carter D;Delahay R.M;Ducommun B;Duijf P.H.G;Epp T;Eskelinen E.-L;Fallah M;Farber D.B;Fernandez-Triana J;Feyerabend F;Florio T;Friebe M;Furuta S;Gabrielsen M;Gruber J;Grybos M;Han Q;Heinrich M;Helanter? H;Huber M;Jeltsch A;Jiang F;Josse C;Jurman G;Kamiya H;de Keersmaecker K;Kristiansson E;de Leeuw F.-E;Li J;Liang S;Lopez-Escamez J.A;Lopez-Ruiz F.J;Marchbank K.J;Marschalek R;Mart?n C.S;Miele A.E;Montagutelli X;Morcillo E;Nicoletti R;Niehof M;O'Toole R;Ohtomo T;Oster H;Palma J.-A;Paterson R;Peifer M;Portilla M;Portillo M.C;Pritchard A.L;Pusch S;Raghava G.P.S;Roberts N.J;Ross K;Schuele B;Sergeant K;Shen J;Stella A;Sukocheva O;Uversky V.N;Vanneste S;Villet M.H;Viveiros M;Vorholt J.A;Weinstock C;Yamato M;Zabetakis I;Zhao X;Ziegler A;Aizat W.M;Atlas L;Bridges K.M;Chakraborty S;Deschodt M;Domingues H.S;Esfahlani S.S;Falk S;Guisado J.L;Kane N.C;Kueberuwa G;Lau C.L;Liang D;Liu E;Luu A.M;Ma C;Ma L;Moyer R;Norris A.D;Panthee S;Parsons J.R;Peng Y;Pinto I.M;Reschke C.R;Sillanp?? E;Stewart C.J;Uhle F;Yang H;Zhou K;Zhu S;Ashry M;Bergsland N;Berthold M;Chen C.-E;Colella V;Cuypers M;Eskew E.A;Fan X;Gajda M;Gonz?lezlez-Prendes R;Goodin A;Graham E.B;Groen E.J.N;Guti?rrez-Sacrist?n A;Habes M;Heffler E;Higginbottom D.B;Janzen T;Jayaraman J;Jibb L.A;Jongen S;Kinyanjui T;Koleva-Kolarova R.G;Li Z;Liu Y.-P;Lund B.A;Lussier A.A;Ma L;Mier P;Moore M.D;Nagler K;Orme M.W;Pearson J.A;Prajapati A.S;Saito Y;Tr?der S.E;Uchendu F;Verloh N;Voutchkova D.D;Abu-Zaid A;Bakkach J;Baumert P;Dono M;Hanson J;Herbelet S;Hobbs E;Kulkarni A;Kumar N;Liu S;Loft N.D;Reddan T;Senghore T;Vindin H;Xu H;Bannon R;Chen B;Cheung J.T.K;Cooper J;Esnakula A.K;Feghali K.A;Ghelardi E;Gnasso A;Horbar J;Lai H.M;Li J;Ma L;Ma R;Pan Z;Peres M.A;Pranata R;Seow E;Sydes M;Testoni I;Westermair A.L;Yang Y;Afnan M;Albiol J;Albuquerque L.G;Amir S;Amiya E;Amorim R.M;An Q;Andersen S.U;Aplin J.D;Argyropoulos C;Asmann Y.W;Assaeed A.M;Atanasov A.G;Atchison D.A;Avery S.V;Avillach P;Baade P.D;Backman L;Badie C;Baldi A;Ball E;Bardot O;Barnett A.G;Basner M;Batra J;Bazanova O.M;Beale A;Beddoe T;Bell M.L;Berezikov E;Berners-Price S;Bernhardt P;Berry E;Bessa T.B;Billington C;Birch J;Blakely R.D;Blaskovich M.A.T;Blum R;Boelaert M;Bogdanos D;Bosch C;Bourgoin T;Bouvard D;Boykin L.M;Bradley G;Braun D;Brownlie J;Br?hl A;Burt A;Butler L.M;Byrareddy S.N;Byrne H.J;Cabantous S;Calatayud S;Candal E;Carlson K;Casillas S;Castelvetro V;Caswell P.T;Cavalli G;Cerovsky V;Chagoyen M;Chen C.-S;Chen D.F;Chen H;Chen H;Chen J.-T;Chen Y;Cheng C;Cheng J;Chinapaw M;Chinopoulos C;Cho W.C.S;Chong L;Chowdhury D;Chwalibog A;Ciresi A;Cockcroft S;Conesa A;Cook P.A;Cooper D.N;Coqueret O;Corea E.M;Costa A;Costa E;Coupland C;Crawford S.Y;Cruz A.D;Cui H;Cui Q;Culver D.C;D'Angiulli A;Dahms T.E.S;Daigle F;Dalgleish R;Danielsen H.E;Darras S;Davidson S.M;Day D.A;Degirmenci V;Demaison L;Devriendt K;Ding J;Dogan Y;Dong X.C;Donner C.F;Dressick W;Drevon C.A;Duan H;Ducho C;Dumaz N;Dwarakanath B.S;Ebell M.H;Eisenhardt S;Elkum N;Engel N;Erickson T.B;Fairhead M;Faville M.J;Fejzo M.S;Festa F;Feteira A;Flood-Page P;Forsayeth J;Fox S.A;Franks S.J;Frentiu F.D;Frilander M.J;Fu X;Fujita S;Galea I;Galluzzi L;Gani F;Ganpule A.P;Garc?a-Alix A;Gedye K;Giordano M;Giunta C;Gleeson P.A;Goarant C;Gong H;Gora D;Gough M.J;Goyal R;Graham K.E;Grande-P?rez A;Graves P.M;Greidanus H;Grice D;Grunau C;Gumulya Y;Guo Y;Gurevich V.V;Gusev O;Hacker E;Hage S.R;Hagen G;Hahn S;Haller D.M;Hammerschmidt S;Han J;Han R;Handfield M;Hapuarachchi H.C;Harder T;Hardingham J.E;Heck M;Heers M;Hew K.F;Higuchi Y;Hilaire C.St;Hilton R;Hodzic E;Hone A;Hongoh Y;Hu G;Huber H.P;Hueso L.E;Huirne J;Hurt L;Idborg H;Ikeo K;Ingley E;Jakeman P.M;Jensen A;Jia H;Jia H;Jia S;Jiang J;Jiang X;Jin Y;Jo D;Johnson A.M;Johnston M;Jonscher K.R;Jorens P.G;Jorgensen J.O.L;Joubert J.W;Jung S.-H;Junior A.M;Kahan T;Kamboj S.K;Kang Y.-K;Karamanos Y;Karp N.A;Kelly R;Kenna R;Kennedy J;Kersten B;Khalaf R.A;Khalid J.M;Khatlani T;Khider T;Kijanka G.S;King S.R.B;Kluz T;Knox P;Kobayashi T;Koch K.-W;Kohonen-Corish M.R.J;Kong X;Konkle-Parker D;Korpela K.M;Kostrikis L.G;Kraiczy P;Kratz H;Krause G;Krebsbach P.H;Kristensen S.R;Kumari P;Kunimatsu A;Kurdak H;Kwon Y.D;Lachat C;Lagisz M;Laky B;Lammerding J;Lange M;Larrosa M;Laslett A.L;Laverman G.D;Leclair E.E;Lee K.-W;Lee M.-Y;Lee M.-S;Li G;Li J;Lieb K;Lim Y.Y;Lindsey M.L;Line P.-D;Liu D;Liu F;Liu H;Liu H;Lloyd V.K;Lo T.-W;Locci E;Loidl J;Lorenzen J;Lorkowski S;Lovell N.H;Lu H;Lu W;Lu Z;Luengo G.S;Lundh L.-G;Lysy P.A;Mabb A;Mack H.G;Mackey D.A;Mahdavi S.R;Maher P;Maher T;Maity S.N;Malgrange B;Mamoulakis C;Mangoni A.A;Manke T;Manstead A.S.R;Mantalaris A;Marsal J;Marschall H.-U;Martin F.L;Martinez-Raga J;Martinez-Salas E;Mathieu D;Matsui Y;Maza E;McCutcheon J.E;McKay G.J;McMillan B;McMillan N;Meads C;Medina L;Merrick B.A;Metzger D.W;Meunier F.A;Michaelis M;Micheau O;Mihara H;Mintz E.M;Mizukami T;Moalic Y;Mohapatra D.P;Monteiro A;Montes M;Moran J.V;Morozov S.Y;Mort M;Murai N;Murphy D.J;Murphy S.K;Murray S.A;Naganawa S;Nammi S;Nasios G;Natoli R.M;Nguyen F;Nicol C;van Nieuwerburgh F;Nilsen E.B;Nobile C.J;O'Mahony M;Ohlsson S;Olatunbosun O;Olofsson P;Ortiz A;Ostrikov K;Otto S;Outeiro T.F;Ouyang S;Paganoni S;Page A;Palm C;Paradies Y;Parsons M.H;Parsons N;Pascal P;Paul E;Peckham M;Pedemonte N;Pellizzon M.A;Petrelli M;Pichugin A;Pinto C.J.C;Plevris J.N;Pollesello P;Polz M;Ponti G;Porcelli P;Prince M;Quinn G.P;Quinn T.J;Ramula S;Rappsilber J;Rehfeldt F;Reiling J.H;Remacle C;Rezaei M;Riddick E.W;Ritter U;Roach N.W;Roberts D.D;Robles G;Rodrigues T;Rodriguez C;Roislien J;Roobol M.J;Rowe A;Ruepp A;van Ruitenbeek J;Rust P;Saad S;Sack G.H;Santos M;Saudemont A;Sava G;Schrading S;Schramm A;Schreiber M;Schuler S;Schymkowitz J;Sczyrba A;Seib K.L;Shi H.-P;Shimada T;Shin J.-S;Shortt C;Silveyra P;Skinner D;Small I;Smeets P.A.M;So P.-W;Solano F;Sonenshine D.E;Song J;Southall T;Speakman J.R;Srinivasan M.V;Stabile L.P;Stasiak A;Steadman K.J;Stein N;Stephens A.W;Stewart D.I;Stine K;Storlazzi C;Stoynova N.V;Strzalka W;Suarez O.M;Sultana T;Sumant A.V;Summers M.J;Sun G;Tacon P;Tanaka K;Tang H;Tanino Y;Targett-Adams P;Tayebi M;Tayyem R;Tebbe C.C;Telfer E.E;Tempel W;Teodorczyk-Injeyan J.A;Thijs G;Thorne S;Thrift A.G;Tiffon C;Tinnefeld P;Tjahjono D.H;Tolle F;Toth E;Del Tredici A.L;Tsapas A;Tsirigotis K;Turak A;Tzotzos G;Udo E.E;Utsumi T;Vaidyanathan S;Vaillant M;Valsesia A;Vandenbroucke R.E;Veiga F.H;Vendrell M;Vesk P.A;Vickers P;Victor V.M;Villemur R;Vohl M.-C;Voolstra C.R;Vuillemin A;Wakelin S;Waldron L;Walsh L.J;Wang A.Y;Wang F;Wang Y;Watanabe Y;Weigert A;Wen J.-C;Wham C;White E.P;Wiener J;Wilharm G;Wilkinson S;Willmann R;Wilson C;Wirth B;Wojan T.R;Wolff M;Wong B.M;Wu T.-W;Wuerbel H;Xiao X;Xu D;Xu J.W;Xu J;Xue B;Yalcin S;Yan H;Yang E.-C;Yang S;Yang W;Ye Y;Ye Z.-Q;Yli-Kauhaluoma J;Yoneyama H;Yu Y;Yuan G.-C;Yuh C.-H;Zaccolo M;Zeng C;Zevnik B;Zhang C;Zhang L;Zhang Y;Zhang Y;Zhang Z;Zhang Z.-Y;Zhao Y;Zhou M;Zuberbier T;Aanei C.M;Ahmad R;Al-Lawama M;Alanio A;Allardyce J;Alonso-Caneiro D;Atack J.M;Baier D;Bansal A;Benezeth Y;Berbesque C;Berrevoet F;Biedermann P.H.W;Bijleveld E;Bittner F;Blombach F;van den Bos W;Boudreau S.A;Bramoweth A.D;Braubach O;Cai Y;Campbell M;Cao Z;Catry T;Chen X;Cheng S;Chung H.-J;Ch?vez-Fumagalli M.A;Conway A;Costa B.M;Cyr N;Dean L.T;Denzel M.S;Dlamini S.V;Dudley K.J;Dufies M;Ecke T;Eckweiler D;Eixarch E;El-Adawy H;Emmrich J.V;Eustace A.J;Falter-Wagner C.M;Farhoudi R;Fuss J;Gao J;Gill M.R;Gloyn L;Goggs R;Govinden U;Greene G;Greiff V;Grundle D.S;Gr?neberg P;Gumede N;Haore G;Harrison P;Hoenner X;Hojsgaard D;Hori H;Ikonomopoulou M.P;Jeurissen P;Johnson D.M;Kabra D;Kamagata K;Karmakar C;Kasian O;Kaye L.K;Khan M.M;Kim Y.-M;Kish J.K;Kobold S;Kohanbash G;Kohls G;Kugler J.-M;Kumar G;Lacy-Colson J;Latif A;Lauschke V.M;Li B;Lim C.J;Liu F;Liu X;Lu J.-J;Lu Q;Mahavadi P;Marzocchi U;McGarrigle C.A;van Meerten T;Min R;Moal I;Molari M;Molleman L;Mondal S.R;van de Mortel T;Moss W.N;Moultos O.A;Mukherjee M;Nakayama K;Narayan E;Navaratnarajah, Neumann P.-A;Nie J;Nie Y;Niemeyer F;Nolan F;Nwaiwu O;Oldenmenger W.H;Olumayede E;Ou J;Pallebage-Gamarallage M;Pearce S.P;Pelkonen T;Pelleri M.C;Pereira J.L;Pheko M;Pinto K.A;Piovesan A;Pluess M;Podolsky I.M;Prescott J;Qi D;Qi X;Raikou V.D;Ranft A;Rhodes J;Rotge J.-Y;Rowe A.D;Saggar M;Schuon R.A;Shahid S;Shalchyan V;Shirvalkar P;Shiryayev O;Singh J;Smout M.J;Soares A;Song C;Srivastava K;Srivastava R.K;Sun J;Szabo A;Szymanski W;Tai C.N.P;Takeuchi H;Tanadini-Lang S;Tang F;Tao W;Theron G;Tian C.F;Tian Y.-S;Tuttle L.M;Valenti A;Verlot P;Walker M;Wang J;Welter D;Winslade M;Wu D;Wu Y.-R;Xiao H;Xu B;Xu J;Xu Z;Yang D;Yang M;Yankilevich P;You Y;Yu C;Zhan J;Zhang G;Zhang K;Zhang T;Zhang Y;Zhao G;Zhao J;Zhou X;Zhu Z;Ajani P.A;Anazodo U.C;Bagloee S.A;Bail K;Bar I;Bathelt J;Benkeser D;Bernier M.L;Blanchard A.M;Boakye D.W;Bonatsos V;Boon M.H;Bouboulis G;Bromfield E;Brown J;Bul K.C.M;Burton K.J;Butkowski E.G;Carroll G;Chao F;Charrier E.E;Chen X;Chen Y.-C;Chenguang, Choi J.R;Christoffersen T;Comel J.C;Cosse C;Cui Y;van Dessel P;Dhaval, Diodato D;Duffey M;Dutt A;Egea L.G;El-Said M;Faye M;Fernandez-Fernandez B;Foley K.G;Founou L.L;Fu F;Gadelkareem R.A;Galimov E;Garip G;Gemmill A;Gouil Q;Grey J;Gridneva Z;Grothe M.J;Gr?bert T;Guerrero F;Guignard L;Haenssgen M.J;Hasler D;Holgate J.Y;Huang A;Hulse-Kemp A.M;Jean-Quartier C;Jeon S.-M;Jia Y;Jutzeler C;Kalatzis P;Karim M;Karsay K;Keitel A;Kempe A;Keown J.R;Khoo C.M;Khwaja N;Kievit R.A;Kosanic S;Koutoukidis D.A;Kramer P;Kumar D;Kira? N;Lanza G;Le T.D;Leem J.W;Leightley D;Leite A;Lercher L;Li Y;Lim R;Lima L.R.A;Lin L;Ling T;Liu Y;Liu Z;Lu Y;Lum F.M;Luo H;Machhi J;Macleod A;Macwan I;Madala H.R;Madani N;de Maio N;Makowiecki K;Mallinson D.J;Margelyte R;Maria C;Markonis Y;Marsili L;Mavoa S;McWilliams L;Megersa M;Souto-Maior C;Menichetti J;Mercieca-Bebber R;Miller J.J;Minde D.-P.M;Minges A;Mishra E;Mishra V.R;Moores C;Morrice N;Moskalensky A.E;Navarin N;Negera E;Nolet P;Nordberg A;Nord?n R;Nowicki J.P;Olova N;Olszewski P;Onzima R;Pan C.-L;Park C;Park D.I;Park S;Patil C.D;Pedro S.A;Perry S.R;Peter J;Peterson B.M;Pezzuolo A;Pozdnyakov I;Qian S;Qin L;Rafe A;Raote I;Raza A;Rebl H;Refai O;Regan T;Richa T;Richardson M.F;Robinson K.R;Rossoni L;Rouet R;Safaei S;Schneeberger P.H.H;Schwotzer D;Sebastian A;Selinski J;Seltmann S;Sha F;Shalev N;Shang J.-L;Singer J;Singh M;Smith T;Solomon-Moore E;Song L;Soraggi S;Stanley R;Steckhan N;Strobl F;Subissi L;Supriyanto I;Surve C.R;Suzuki T;Syme C;S?relius K;Tang Y;Tantawy M;Tennakoon S;Teseo S;Toelzer C;Tomov N;Tovar M;Tran L;Tripathi S;Tuladhar A.M;Ukubuiwe A.C;Ung C.O.L;Valgepea K;Vatanparast H;Vidal A;Wang F;Wang Q;Watari R;Webster R;Webster R;Wei J;Wibowo D;Wingenbach T.S.H;Xavier R.M;Xiao S;Xiong P;Xu S;Xu S;Yao R;Yao W;Yin Q;Yu Y;Zaitsu M;Zeineb Z;Zhan X.-Y;Zhang J;Zhang R;Zhang W;Zhang X;Zheng S;Zhou B;Zhou X;Ahmad H;Akinwumi S.A;Albery G.F;Alhowimel A;Ali J;Alshehri M;Alsuhaibani M;Anikin A;Azubuike S.O;Bach-Mortensen A;Baltiansky L;Bartas M;Belachew K.Y;Bhardwaj V;Binder K;Bland N.S;Boah M;Bullen B;Calabr? G.E;Callahan T.J;Cao B;Chalmers K;Chang W;Che Z;Chen A.T.Y;Chen H;Chen H;Chen Y;Chen Z;Choi Y;Chowdhury M.A.K;Christensen M.R;Cooke R.S.C;Cottini M;Covington N.V;Cunningham C;Delarocque J;Devos L;Dhar A.R;Ding K.-F;Dong K;Dong Z;Dreyer N;Ekstrand C;Fardet T;Feleke B.E;Feurer T;Freitas A;Gao T;Gebremedhin, Giganti F;Grabowski P;Guerra-Mora J.R;Guo C;Guo X;Gupta H;He S;Heijne M;Heinemann S;Hogrebe A;Huang Z;Iskander-Rizk S;Iyer L.M;Jahan Y;James A.S;Joel E;Joffroy B;J?gousse C;Kambondo G;Karnati P;Kaya C;Ke A;Kelly D;Kickert R;Kidibule P.E;Kieselmann J.P;Kim H.J;Kitazawa T;Lamberts A;Li Y;Liang H;Linn S.N;Litfin T;Liusuo W;Lygirou V;Mahato A.K;Mai Z.-M;Major R.W;Mali S;Mallis P;Mao W;Marvin-Dowle K;Mason L.D;Merideth B;Merino-Plaza M.J;Merlaen B;Messina R;Mishra A.K;Muhammad J;Musinguzi C;Nanou A;Naqash A;Nguyen J.T;Nguyen T.T.H;Ni D;Nida, Notcovich S;Ohst B;Ollivier Q.R;Osses D.F;Peng X;Plantinga A;Pulia M;Rafiq M;Raman A;Raucher-Ch?n?, Rawski R;Ray A;Razak L.A;Rudolf K;Rusch P;Sadoine M.L;Schmidt A;Schurr R;Searles S;Sharma S;Sheehan B;Shi C;Shohayeb B;Sommerlad A;Strehlow J;Sun X;Sundar R;Taherzadeh G;Tahir N.D.M;Tang J;Testa J;Tian Z;Tingting Q;Verheijen G.P;Vickstrom C;Wang T;Wang X;Wang Z;Wei P;Wilson A;Wyart, Yassine A.-A;Yousefzadeh A;Zare A;Zeng Z;Zhang C;Zhang H;Zhang L;Zhang T;Zhang W;Zhang Z;Zhou J;Zhu D;Adamo V;Adeyemo A.A;Aggelidou M;Al-Owaifeer A.M;Al-Riyami A.Z;Alzghari S.K;Andersen V;Angus K;Asaduzzaman M;Asady H;Ato D;Bai X;Baines R.L;Ballantyne M;Ban B;Beck J;Ben-Nafa W;Black E;Blancher A;Blankstein R;Bodagh N;Borges P;Brooks A;Brox-Ponce J;Brunetti A;Canham C.D;Carninci P;Carvajal R;Chang S.C;Chao J;Chatterjee P;Chen H;Chen L;Chen Y.-C;Chhatriwalla A.K;Chikowe I;Chuang T.-J;Collevatti R.G;Cornejo D.A.V;Cuenda A;Dao M;Dauga D;Deng Z;Devkota K;Doan L.V;Elewa Y.H.A;Fan D;Faruk M;Feifei S;Ferguson T.S;Fleres F;Foster E.J;Foster S;Furer T;Gao Y;Garcia-Rivera E.J;Gazdar A;George R.B;Ghosh S;Gianchecchi E;Gleason J.M;Hackshaw A;Hall A;Hall R;Harper P;Hogg W.E;Huang G;Hunter K.E;Ijzerman A.P;Jesus C;Jian G;Lewis J.S;Jr;Kanj S.S;Kaur H;Kelly S;Kheir F;Kichatova V.S;Kiyani M;Klein R;Kovesi T;Kraschnewski J.L;Kumar A.P;Labutin D;Lazo-Langner A;Leclercq G;Li M;Li Q;Li T;Li Y;Liao W.-T;Liao Z.-Y;Lin J;Lizer J;Lobreglio G;Lowies C;Lu C;Majeed H;Martin A;Martinez-Sobrido L;Meresh E;Middelveen M;Mohebbi A;Mota J;Mozaheb Z;Muyaya L;Nandhakumar A;Ng S.H.X;Obeidat M;Oh D.-H;Owais M;Pace-Asciak P;Panwar A;Park C;Patterson C;Penagos-Tabaree F;Pianosi P.T;Pinzi V;Pridans C;Psaroulaki A;Pujala R.K;Pulido-Arjona L;Qi P.-F;Rahman P;Rai N.K;Rassaf T;Refardt J;Ricciardi W;Riess O;Rovas A;Sacks F.M;Saleh S;Sampson C;Schmutz A;Sepanski R;Sharma N;Singh M;Spearman P;Subramaniapillai M;Swali R;Tan C.M;Tellechea J.I;Thomas L.-M;Tong X;Vavvas D.G;Veys R;Vitriol V;Wang H.-D;Wang J;Wang J;Waugh J;Webb S.A;Williams B.A;Workman A.D;Xiang T;Xie L.-X;Xu J;Xu T;Yang C;Yoon J.G;Yuan C.M;Zaritsky A;Zhang Y;Zhao H;Zuckerman H;Lyu R;Pullan W;RELISH Consortium; Brown P; EN-CHENG YANG et al. |
| 臺大學術典藏 |
2021-07-03T03:33:57Z |
Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: Results of a randomized phase III trial
|
Cainap C.; Qin S.; Huang W.-T.; Chung I.J.; Pan H.; Cheng Y.; Kudo M.; Kang Y.-K.; PEI-JER CHEN; Toh H.-C.; Gorbunova V.; Eskens F.A.L.M.; Qian J.; McKee M.D.; Ricker J.L.; Carlson D.M.; El-Nowiem S. |
| 臺大學術典藏 |
2021-03-18T02:02:48Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.;Kang Y.K.;Yang T.-S.;Chia-Tung Shun;Shao Y.-Y.;Su W.-C.;Sandoval-Tan J.;Chiou T.-J.;Jin K.;Hsu C.;Cheng A.-L.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN; Shao Y.-Y.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Hsu C.; Cheng A.-L. |
| 臺大學術典藏 |
2021-02-19T06:52:26Z |
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
|
Yen C.-J.;Kudo M.;Lim H.-Y.;Chih-Hung Hsu;Vogel A.;Brandi G.;Cheng R.;Nitu I.S.;Abada P.;Hsu Y.;Zhu A.X.;Kang Y.-K.; Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. |
| 臺大學術典藏 |
2021-02-19T06:52:25Z |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu A.X.;Finn R.S.;Kang Y.-K.;Yen C.-J.;Galle P.R.;Llovet J.M.;Assenat E.;Brandi G.;Motomura K.;Ohno I.;Daniele B.;Vogel A.;Yamashita T.;Chih-Hung Hsu;Gerken G.;Bilbruck J.;Hsu Y.;Liang K.;Widau R.C.;Wang C.;Abada P.;Kudo M.; Zhu A.X.; Finn R.S.; Kang Y.-K.; Yen C.-J.; Galle P.R.; Llovet J.M.; Assenat E.; Brandi G.; Motomura K.; Ohno I.; Daniele B.; Vogel A.; Yamashita T.; CHIH-HUNG HSU; Gerken G.; Bilbruck J.; Hsu Y.; Liang K.; Widau R.C.; Wang C.; Abada P.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:13Z |
Corrigendum to Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Dela Cruz C.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Dela Cruz C.; Kudo M. |
| 臺大學術典藏 |
2021-02-18T02:09:12Z |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.;Kang Y.-K.;Kim T.-Y.;El-Khoueiry A.B.;Santoro A.;Sangro B.;Melero I.;Kudo M.;Hou M.-M.;Matilla A.;Tovoli F.;Knox J.J.;Ruth He A.;El-Rayes B.F.;Acosta-Rivera M.;Lim H.-Y.;Neely J.;Shen Y.;Wisniewski T.;Anderson J.;Chiun Hsu; Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; Chiun Hsu |
| 臺大學術典藏 |
2021-01-28T01:06:35Z |
Management of gastric cancer in Asia: Resource-stratified guidelines
|
Shen L.;Shan Y.-S.;Hu H.-M.;Price T.J.;Sirohi B.;Kun-Huei Yeh;Yang Y.-H.;Sano T.;Yang H.-K.;Zhang X.;Park S.R.;Fujii M.;Kang Y.-K.;Chen L.-T.; Shen L.; Shan Y.-S.; Hu H.-M.; Price T.J.; Sirohi B.; KUN-HUEI YEH; Yang Y.-H.; Sano T.; Yang H.-K.; Zhang X.; Park S.R.; Fujii M.; Kang Y.-K.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:25Z |
Anti-angiogenic therapy in patients with advanced gastric and gastroesophageal junction cancer: A systematic review
|
Chen L.-T.;Oh D.-Y.;Ryu M.-H.;Kun-Huei Yeh;Yeo W.;Carlesi R.;Cheng R.;Kim J.;Orlando M.;Kang Y.-K.; Chen L.-T.; Oh D.-Y.; Ryu M.-H.; KUN-HUEI YEH; Yeo W.; Carlesi R.; Cheng R.; Kim J.; Orlando M.; Kang Y.-K. |
| 臺大學術典藏 |
2021-01-28T01:06:21Z |
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Kang Y.-K.;Boku N.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Chen L.-T.; Kang Y.-K.; Boku N.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Chen L.-T. |
| 臺大學術典藏 |
2021-01-28T01:06:17Z |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh T.; Kang Y.-K.; Chao Y.; Ryu M.-H.; Kato K.; Cheol Chung H.; Chen J.-S.; Muro K.; Ki Kang W.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Tanimoto M.; Chen L.-T.; Boku N. |
| 臺大學術典藏 |
2021-01-28T01:06:16Z |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen L.-T.;Satoh T.;Ryu M.-H.;Chao Y.;Kato K.;Chung H.C.;Chen J.-S.;Muro K.;Kang W.K.;Kun-Huei Yeh;Yoshikawa T.;Oh S.C.;Bai L.-Y.;Tamura T.;Lee K.-W.;Hamamoto Y.;Kim J.G.;Chin K.;Oh D.-Y.;Minashi K.;Cho J.Y.;Tsuda M.;Sameshima H.;Kang Y.-K.;Boku N.; Chen L.-T.; Satoh T.; Ryu M.-H.; Chao Y.; Kato K.; Chung H.C.; Chen J.-S.; Muro K.; Kang W.K.; KUN-HUEI YEH; Yoshikawa T.; Oh S.C.; Bai L.-Y.; Tamura T.; Lee K.-W.; Hamamoto Y.; Kim J.G.; Chin K.; Oh D.-Y.; Minashi K.; Cho J.Y.; Tsuda M.; Sameshima H.; Kang Y.-K.; Boku N. |
| 國立成功大學 |
2021 |
Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2
|
Kudo, M.;Galle, P.R.;Brandi, G.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Llovet, J.M.;Assenat, E.;Merle, P.;Chan, S.L.;Palmer, D.H.;Ikeda, M.;Yamashita, T.;Vogel, A.;Huang, Y.-H.;Abada, P.B.;Yoshikawa, R.;Shinozaki, K.;Wang, C.;Widau, R.C.;Zhu, A.X. |
| 國立成功大學 |
2021 |
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab
|
Zhu, A.X.;Finn, R.S.;Kang, Y.-K.;Yen, C.-J.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Motomura, K.;Ohno, I.;Daniele, B.;Vogel, A.;Yamashita, T.;Hsu, C.-H.;Gerken, Gerken G.;Bilbruck, J.;Hsu, Y.;Liang, K.;Widau, R.C.;Wang, C.;Abada, P.;Kudo, M. |
| 國立成功大學 |
2021 |
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
|
Boku, N.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Nishiyama, T.;Chen, L.-T.;Kang, Y.-K. |
| 臺大學術典藏 |
2020-05-25T07:35:00Z |
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors
|
Ansell P; Motwani M; Wong S; Yue H; Wang L; Reilly E; Afar D; Naumovski L; Ramanathan R.K.; Strickler J.H; LoRusso P; Salgia R; Kang Y.-K; Yen C.J; Chia-Chi Lin |
| 臺大學術典藏 |
2020-04-10T12:51:11Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.-H.; Kang Y.K.; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; Chiun Hsu; Cheng A.-L.; Yang T.-S.; Shun C.-T.; Shao Y.-Y. |
| 臺大學術典藏 |
2020-04-10T12:51:02Z |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
Melero I.; Dastani H.B.; Tang H.; Neely J.; El-Khoueiry A.B.;Sangro B.;Yau T.;Crocenzi T.S.;Kudo M.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Trojan J.;Welling T.H.;3Rd, Meyer T.;Kang Y.-K.;Yeo W.;Chopra A.;Anderson J.;Dela Cruz C.;Lang L.;Neely J.;Tang H.;Dastani H.B.;Melero I.; El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L. |
| 臺大學術典藏 |
2020-04-10T12:16:09Z |
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study
|
Hsu C.; Cheng A.-L.; Jin K.; Hsu C.-H.; Kang Y.K.; Yang T.-S.; Shun C.-T.; YU-YUN SHAO; Su W.-C.; Sandoval-Tan J.; Chiou T.-J. |
| 臺大學術典藏 |
2020-02-19T07:21:49Z |
E2/estrogen receptor/Sjogren syndrome-associated autoantigen relieves coactivator activator-induced G1/S arrest to promote breast tumorigenicity
|
MING-JER TSAI; Kang Y.K.; Jung S.Y.; Qin J.; Li C.; Tsai S.Y.; Tsai M.-J.; O'Malley B.W. |
| 臺大學術典藏 |
2020-02-19T07:21:48Z |
CAPER Is Vital for Energy and Redox Homeostasis by Integrating Glucose-Induced Mitochondrial Functions via ERR-�\-Gabpa and Stress-Induced Adaptive Responses via NF-�eB-cMYC
|
Kang Y.K.; Putluri N.; Maity S.; Tsimelzon A.; Ilkayeva O.; Mo Q.; Lonard D.; Michailidis G.; Sreekumar A.; Newgard C.B.; Wang M.; Tsai S.Y.; Tsai M.-J.; O'Malley B.W.; MING-JER TSAI |
| 臺大學術典藏 |
2020 |
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
|
Yau T.; Kang Y.-K.; Kim T.-Y.; El-Khoueiry A.B.; Santoro A.; Sangro B.; Melero I.; Kudo M.; Hou M.-M.; Matilla A.; Tovoli F.; Knox J.J.; Ruth He A.; El-Rayes B.F.; Acosta-Rivera M.; Lim H.-Y.; Neely J.; Shen Y.; Wisniewski T.; Anderson J.; CHIUN HSU |
| 國立成功大學 |
2020 |
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies
|
Yen, C.-J.;Kudo, M.;Lim, H.-Y.;Hsu, C.-H.;Vogel, A.;Brandi, G.;Cheng, R.;Nitu, I.S.;Abada, P.;Hsu, Y.;Zhu, A.X.;Kang, Y.-K. |
| 國立成功大學 |
2020 |
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
|
Desai, J.;Deva, S.;Lee, J.S.;Lin, C.-C.;Yen, C.-J.;Chao, Y.;Keam, B.;Jameson, M.;Hou, M.-M.;Kang, Y.-K.;Markman, B.;Lu, C.-H.;Rau, K.-M.;Lee, K.-H.;Horvath, L.;Friedlander, M.;Hill, A.;Sandhu, Sandhu S.;Barlow, P.;Wu, C.-Y.;Zhang, Y.;Liang, Liang L.;Wu, J.;Paton, V.;Millward, Millward M. |
| 國立成功大學 |
2020 |
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
|
Chen, L.-T.;Satoh, T.;Ryu, M.-H.;Chao, Y.;Kato, Kato K.;Chung, H.C.;Chen, J.-S.;Muro, K.;Kang, W.K.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Sameshima, H.;Kang, Y.-K.;Boku, N. |
| 國立成功大學 |
2020 |
Phase I dose-escalation and -expansion study of telisotuzumab (ABT-700), an Anti-c-met antibody, in patients with advanced solid tumors
|
Strickler, J.H.;LoRusso, P.;Salgia, R.;Kang, Y.-K.;Yen, C.J.;Lin, C.-C.;Ansell, P.;Motwani, Motwani M.;Wong, S.;Yue, H.;Wang, L.;Reilly, E.;Afar, D.;Naumovski, L.;Ramanathan, Ramanathan R.K. |
| 國立成功大學 |
2020 |
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
|
Satoh, T.;Kang, Y.-K.;Chao, Y.;Ryu, M.-H.;Kato, Kato K.;Cheol, Chung H.;Chen, J.-S.;Muro, K.;Ki, Kang W.;Yeh, K.-H.;Yoshikawa, T.;Oh, S.C.;Bai, L.-Y.;Tamura, Tamura T.;Lee, K.-W.;Hamamoto, Y.;Kim, J.G.;Chin, K.;Oh, D.-Y.;Minashi, K.;Cho, J.Y.;Tsuda, M.;Tanimoto, M.;Chen, L.-T.;Boku, N. |
| 臺大學術典藏 |
2019 |
Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
|
Yau T.;Chiun Hsu;Kim T.-Y.;Choo S.-P.;Kang Y.-K.;Hou M.-M.;Numata K.;Yeo W.;Chopra A.;Ikeda M.;Kuromatsu R.;Moriguchi M.;Chao Y.;Zhao H.;Anderson J.;Cruz C.D.;Kudo M.; Yau T.; Chiun Hsu; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.; Yeo W.; Chopra A.; Ikeda M.; Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M. |
| 國立成功大學 |
2019 |
Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (a
|
Boku, N.;Ryu, M.-H.;Kato, Kato K.;Chung, H.C.;Minashi, K.;Lee, K.-W.;Cho, H.;Kang, W.K.;Komatsu, Y.;Tsuda, M.;Yamaguchi, K.;Hara, Hara H.;Fumita, S.;Azuma, M.;Chen, L.-T.;Kang, Y.-K. |
| 國立成功大學 |
2019 |
Effect of First-line S-1 Plus Oxaliplatin with or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial
|
Yoshikawa, T.;Muro, K.;Shitara, K.;Oh, D.-Y.;Kang, Y.-K.;Chung, H.C.;Kudo, T.;Chin, K.;Kadowaki, S.;Hamamoto, Y.;Hironaka, S.;Yoshida, K.;Yen, C.-J.;Omuro, Y.;Bai, L.-Y.;Maeda, K.;Ozeki, A.;Yoshikawa, R.;Kitagawa, Y. |
| 國立成功大學 |
2019 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
|
Kato, Kato K.;Satoh, T.;Muro, K.;Yoshikawa, T.;Tamura, Tamura T.;Hamamoto, Y.;Chin, K.;Minashi, K.;Tsuda, M.;Yamaguchi, K.;Machida, N.;Esaki, T.;Goto, M.;Komatsu, Y.;Nakajima, T.E.;Sugimoto, N.;Yoshida, K.;Oki, E.;Nishina, T.;Tsuji, A.;Fujii, H.;Kunieda, Kunieda K.;Saitoh, Saitoh S.;Omuro, Y.;Azuma, M.;Iwamoto, Y.;Taku, K.;Fushida, S.;Chen, L.-T.;Kang, Y.-K.;Boku, N. |
